These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2857173)

  • 21. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.
    Zalman LS; Wood LM; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1986 Sep; 83(18):6975-9. PubMed ID: 2428045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence of direct insertion of terminal complement proteins into cell membrane bilayers during cytolysis. Labeling by a photosensitive membrane probe reveals a major role for the eighth and ninth components.
    Steckel EW; Welbaum BE; Sodetz JM
    J Biol Chem; 1983 Apr; 258(7):4318-24. PubMed ID: 6833260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Membrane attack by complement.
    Podack ER; Tschopp J
    Mol Immunol; 1984 Jul; 21(7):589-603. PubMed ID: 6379417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
    Rollins SA; Sims PJ
    J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
    Lehto T; Meri S
    J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of complement-induced [14C]sucrose release by intracellular and extracellular monoclonal antibodies to C9: evidence that C9 is a transmembrane protein.
    Morgan BP; Luzio JP; Campbell AK
    Biochem Biophys Res Commun; 1984 Jan; 118(2):616-22. PubMed ID: 6704099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activities.
    Tschopp J; Masson D; Schäfer S; Peitsch M; Preissner KT
    Biochemistry; 1988 May; 27(11):4103-9. PubMed ID: 2458130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex.
    Kochi SK; Johnson RC; Dalmasso AP
    J Immunol; 1991 Jun; 146(11):3964-70. PubMed ID: 2033266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The membrane attack mechanism of complement: photolabeling reveals insertion of terminal proteins into target membrane.
    Hu VW; Esser AF; Podack ER; Wisnieski BJ
    J Immunol; 1981 Jul; 127(1):380-6. PubMed ID: 7240749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complement lysis: the ultrastructure and orientation of the C5b-9 complex on target sheep erythrocyte membranes.
    Tranum-Jensen J; Bhakdi S; Bhakdi-Lehnen B; Bjerrum OJ; Speth V
    Scand J Immunol; 1978; 7(1):45-6. PubMed ID: 635472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
    Meri S; Morgan BP; Davies A; Daniels RH; Olavesen MG; Waldmann H; Lachmann PJ
    Immunology; 1990 Sep; 71(1):1-9. PubMed ID: 1698710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
    Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
    J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.
    Milis L; Morris CA; Sheehan MC; Charlesworth JA; Pussell BA
    Clin Exp Immunol; 1993 Apr; 92(1):114-9. PubMed ID: 7682159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
    Tschopp J; Chonn A; Hertig S; French LE
    J Immunol; 1993 Aug; 151(4):2159-65. PubMed ID: 8345200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The C8-binding protein of human erythrocytes: interaction with the components of the complement-attack phase.
    Schönermark S; Filsinger S; Berger B; Hänsch GM
    Immunology; 1988 Apr; 63(4):585-90. PubMed ID: 3366469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electron spin resonance studies on interaction of complement proteins with erythrocyte membranes.
    Dahl CE; Levine RP
    Proc Natl Acad Sci U S A; 1978 Oct; 75(10):4930-4. PubMed ID: 217005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of the membrane attack complex of complement. Evidence that C8 gamma is not the target of homologous restriction factors.
    Davé SJ; Sodetz JM
    J Immunol; 1990 Apr; 144(8):3087-90. PubMed ID: 2324496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multimeric C9 within C5b-9 deposits in unique locations in the cell wall of Salmonella typhimurium.
    Joiner KA; Tartanian AB; Hammer CH; Schweinle JE
    J Immunol; 1989 Jun; 142(12):4450-7. PubMed ID: 2656866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between complement and melittin hemolysis: anti-melittin antibodies inhibit complement lysis.
    Laine RO; Morgan BP; Esser AF
    Biochemistry; 1988 Jul; 27(14):5308-14. PubMed ID: 2458761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorescence resonance energy transfer study of the associative state of membrane-bound complexes of complement proteins C5b-8.
    Cheng KH; Wiedmer T; Sims PJ
    J Immunol; 1985 Jul; 135(1):459-64. PubMed ID: 3923109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.